Cargando…
Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection...
Autores principales: | Kontopoulou, Konstantina, Ainatzoglou, Alexandra, Nakas, Christos T., Ifantidou, Athina, Goudi, Georgia, Antoniadou, Eleni, Adamopoulos, Vasilios, Papadopoulos, Nikitas, Papazisis, Georgios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325516/ https://www.ncbi.nlm.nih.gov/pubmed/34344551 http://dx.doi.org/10.1016/j.vaccine.2021.07.065 |
Ejemplares similares
-
Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers
por: Kontopoulou, Konstantina, et al.
Publicado: (2021) -
Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study
por: Kontopoulou, Konstantina, et al.
Publicado: (2021) -
Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece
por: Kontopoulou, Konstantina, et al.
Publicado: (2022) -
Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status †
por: Stamoula, Eleni, et al.
Publicado: (2022) -
Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)